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Abstract 
 
Multiple sclerosis (MS) is the most common disabling chronic disease of the central nervous 
system among young adults. These patients suffer from variety of symptoms that have a 
profound affect on their working ability, activities of daily living and general quality of life. 
Treatment of these symptoms is important in order to relief them and improve daily function 
and quality of life. Many of these symptoms are often resistant to treatment. Botulinum toxin 
A (BTX) is mainly used for spasticity and bladder dysfunction in MS. It is an effective 
treatment option for spasticity of the thigh adductor, pes equinus, striatal toe or adductor of 
the shoulder joint. BTX injections are effective in reducing incontinence episodes and urinary 
urgency, daytime frequency and nocturia, as well as sustained improvements in quality of life 
of MS patients with detrusor overreactivity. In addition, BTX is potentially effective in 
treating pain, trigeminal neuralgia, tremor, neuro-ophthalmologic complications, facial 
myokymia, gastroparesis, sialorrhea, and hyperhidrosis, however no studies have confirmed 
its efficacy in MS patients. 
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Introduction 
 
Multiple sclerosis (MS) is a chronic disease of the white matter of the central nervous system 
in which patients suffer from a variety of disabling symptoms that greatly affect their 
working ability, activities of daily living and quality of life. MS symptoms are usually 
undertreated due to the lack of awareness on the part of patients and physicians to the 
relevance of symptoms such as fatigue and pain or because many of the available drugs for 
the treatment of MS are off-label and therefore are not available to the patients. Moreover, 
evidence- or expert-based consensus treatment guidelines have been developed for only 
selected MS symptoms (1). Many of these symptoms, even when they are recognized, are 
resistant to treatment and show only partial response to medications. Botulinum toxin 
injections may present additional effective therapeutic options for various MS symptoms.  
 Botulinum toxin is produced by the bacterium Clostridium botulinum. It blocks 
presynaptic release of acetylcholine from nicotinic (neuromuscular junction) and muscarinic 
nerves. Therapeutic injections of botulinum toxin have been in use since the early 1980s. The 
toxin is available in two serotypes, type A (botulinum toxin-A) (BTX) and type B (botulinum 
toxin-B). There are two widely available formulations of BTX, Botox® and Dysport®. 
Importantly, these two formulations of BTX are not dose equivalent, largely for technical 
reasons. The main areas of BTX application in MS include spasticity and bladder 
dysfunction, but many other indications, such as pain management or neuro-ophthalmologic 
complications are potential indications as well. Many of these symptoms are not exclusively 
domain of the neurologist, so multidisciplinary approach between neurologist, urologist, 
ophthalmologist and physical therapist is of paramount inmportance. 
 This review will summarize current understanding on the application of BTX in 
symptomatic management of MS patients.  
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Spasticity  
 
Spasticity is a motor disorder characterized by a velocity-dependent increase in tonic stretch 
reflexes (muscle tone) with exaggerated tendon jerks, resulting from hyperexcitability of the 
stretch reflex, as one component of the upper motor neuron syndrome. (2) Decisions of when 
to start treating spasticity rely on a number of factors, and the balance between negative and 
positive symptoms of upper motor neuron syndrome should influence the selection of an 
appropriate treatment. It should be emphasized that chronic spasticity reflects not only reflex 
resistance, but also resistance of rheologic (contractures, stiffness) origin. This also 
significantly influences treatment selection.  Treatment decisions should always take into 
accounts the patient's overall clinical and social situation, the duration, severity and 
distribution of spasticity, the locus of injury and all the co-morbidities.(3) Urinary tract 
infections, urolithiasis, stool impaction, pressure sores, fractures, dislocations, ingrown 
toenails, and excessively restrictive clothing should always be ruled out before starting any 
treatment. It should also be borne in mind that optimal efficacy of any antispasticity treatment 
that is intended to relax a muscle requires physiotherapy to lengthen the muscle. 
 Before starting treatment for spasticity in MS, the expectations from the treatment 
should be discussed with the patient. Only in rare cases will active functional goals be 
achieved (this is especially relevant in overcoming the spasticity of MS relapse). The more 
realistic goals are pain relief, decrease in muscle spasm frequency, improvement in mobility 
or wheelchair propulsion, transfers, self-care, eating, and return to sexual activity and routine 
activities of daily living. This should be clearly explained to the patient to ensure that the 
expected outcome is realistic and acceptable.      
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 Multiple sclerosis is a common cause of diffuse or regional muscle overactivity where 
the number of affected muscle groups may not be amenable to local treatments. In MS it is 
particularly difficult to assess the functional disability due to spasticty and the functional 
benefit due to treatment, so this is why it appears more appropriate to use therapeutic options 
with transitory effects like BTX. (4) The absolute and comparative efficacy and tolerability of 
anti-spasticity agents in multiple sclerosis is poorly documented and no recommendations can 
be made to guide prescribing. The rationale for treating features of the upper motor neurone 
syndrome must be better understood and sensitive, validated spasticity measures need to be 
developed. (5) Neverthless, there are some situations in which BTX treatment will be 
effective, specifically, leg adductor spasticity, spastic pes equinus and striatal toe. (6). Only 
about 7% of MS patients receive treatment of the upper extremity, mostly due to severe 
adductor spasticity of the shoulder joint (6). BTX usually can not help in enhancing the 
functional capacity of muscle weakness, but it can open a therapeutic window for other 
treatments for bedridden patients by lessening the amount of spasticity, and BTX will help in 
reducing the formation of decubital ulcers and the levels of pain. 
 The first study that showed efficacy of BTX in the treatment of spasticity was 
performed in 1990. Using a randomized crossover design, Snow and coworkers injected BTX 
400 U (Botox®) into the thigh adductor muscles (adductor brevis 100 U, adductor longus 100 
U, adductor magnus 200 U) to 10 non-ambulatory MS patients who had spastic contraction of 
the thigh adductor muscles that interfered with sitting, positioning, cleaning, and urethral 
catheterization. (7) The patients were followed for 6 weeks, and a crossover injection to the 
alternate therapy was performed at three months. The results showed a significant benefit of 
BTX versus placebo at 6 weeks in terms of reduction of the spasticity and hygiene scores, 
and there were no adverse events. A subsequent uncontrolled study on two patients with 
severe lower extremity spasticity showed an improvement in spasticity and in functional 
 6
status, but emphasized the possibility of reduction in muscle tone not only in injected 
muscles, but in non-injected muscles in the region as well. (8) 
 To further determine appropriate muscle selection in treatment of spasticity, Finsterer 
and coworkers used turn/amplitude analysis as an electromyographic (EMG) criterion, on 9 
patients with severe spasticity (5 of them with MS). (9) Those authors used 40-240 MU of 
Dysport® and the patients achieved significant improvements in activities of daily living, 
pain, tone and range of motion. Hyman et al. then performed a placebo-controlled, dose-
dependent study to assess the effect of three different doses of Dysport® (500, 1000, and 1500 
U) in order to define a safe and effective dose for the treatment of hip adductor spasticity in 
patients with MS. (10) Altogether, 74 patients with disabling spasticity of the hip adductor 
muscles (Kurtzke EDS score >7), which caused moderate pain or difficulty in nursing care 
(hygiene score >2), were included. The results showed an improvement in distance between 
the knees for the 1500 U group, muscle tone reduction in all Dysport groups and 
improvement in hygiene scores in the 1000 U and 1500 U groups. Duration of benefit was 
significantly longer than placebo for all Dysport® groups (p<0.05). Importantly, all of these 
benefits were evident despite the extensive use of concomitant oral antispasticity medication 
and analgesics. The most frequent adverse events in the patients treated with Dysport were 
hypertonia (new or worsening spasticity) of injected and/or non-injected muscles (22%), 
weakness of non-injected muscles (14%), fatigue (7%), urinary tract infection (5%), headache 
(5%), micturition frequency (5%), back pain (5%), and diarrhea (5%). A risk-benefit 
assessment of that study suggested that the optimal starting dose for treating hip adductor 
spasticity in MS is 500–1000 U of Dysport® , divided between the two legs, with subsequent 
dose titration as required. One small, uncontrolled study showed that BTX is an efficient drug 
relieving pain in patients with spastic paraparesis, but only the use of high doses of BTX 
(bilaterally 400 U of Botox® or 2000 U of Dysport®) resulted in spasticity relief in lower 
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extremities and significantly increased the range of passive movements in articulations, 
which made care and rehabilitation easier. (11) Another study evaluated the effect of BTX 
(Botox®) on painful tonic spasms in MS patients. (12) The BTX was injected into the forearm 
finger flexor (80 units) and the flexor ulnaris carpi (80 units) for the upper limbs and on the 
gastrocnemius muscle (120 U) and the small flexor foot muscles (50 units) for the lower 
limbs. The pain intensity scores and the daily number of painful tonic spasms were 
significantly reduced in all 5 treated patients at days 8, 30 and 90. Only one study evaluated 
the safety of botulinum toxin type B in the treatment of lower-limb adductor spasticity in 
patients with MS. (13) Results of this study suggested that a starting dose of 30000 U of 
botulinum toxin type B could be safely utilized in the treatment of adductor spasticity in MS, 
but additional studies are needed to evaluate efficacy.  
 
 As noted above, optimal efficacy of antispasticity treatment requires concomitant 
physiotherapy to obtain the maximum benefit. The first randomized controlled trial that 
investigated the potential efficacy of BTX in combination with neurological rehabilitation to 
treat MS-related spasticity demonstrated the benefit of combination therapy consisting of 
BTX injection plus strengthening exercises. (14) That study however suffers from some 
limitations: the sample size was small and the functional outcome measures that are usually 
employed in clinical practice, such as the range of motion, spasm frequency scale and joint 
resting angles, were not applied. 
 In conclusion, BTX is an effective treatment option for spasticity in MS, mostly for 
treating adductor spasticity, pes equinus, striatal toe and adductor spasticity of the shoulder 
joint. The recommended doses are outlined in table 1. (15, 16) A maximum dose of 1500 
units Dysport® (400 units Botox®) per treatment session and 250 U Dysport® (50 U Botox®) 
per injection site is recommended and for evaluation of treatment effects in hip adductor 
spasticity clinical examination with specific scales and measurements is recommended. (17) 
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There is, however, only one placebo-controlled, dose-dependent study of Dysport® for 
treating adductor spasticity in MS. Further studies for the other above-mentioned indications 
are needed to assess the safety, efficacy and cost-effectives of BTX treatment in MS. (18) 
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Table 1. Indications and dosage of BTX in the treatment of spasticity in MS. (15,16) 
Indication Muscles injected Dosage (U) Botox® Dosage (U) Dysport® 
Adductor 
spasticity* 
Adductor magnus 
Adductor longus  
Hamstrings (optional) 
≥100/muscle/side 300/muscle/side 
 
Pes equinus Gastrocnemius – 
medial head 
Gastrocnemius – 
lateral head 
100/muscle/side 
 
100/muscle/side 
150-400/muscle/side 
 
150-400/muscle/side 
Striatal toe Extensor hallucis 
longus 
20-50/muscle/side 100-150/muscle/side 
Adductor 
spasticity of 
the shoulder 
joint 
Pectoralis major 
Latissimus dorsi 
Teres muscle group 
Subscapularis 
75/muscle/side 
80/muscle/side 
30/muscle/side 
50/muscle/side 
200-300/muscle/side 
150-300/muscle/side 
100/muscle/side 
100-150/muscle/side 
*Confirmed by a placebo-controlled, dose-dependent study 
 
Bladder dysfunction 
 
The synergy between the detrusor muscle and the external urethral sphincter is controlled by 
a specific area in the caudal brainstem, the pontine micturition center. Disruption of the 
pathways between this area and the caudal part of the spinal cord often results in detrusor-
sphincter dyssynergia (DSD) (19). DSD has been defined as a detrusor contraction concurrent 
with an involuntary contraction of the urethral and/or periurethral striated muscle (20). DSD 
typically occurs in patients with a supra-sacral lesion (e.g., those with MS) and implies an 
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involuntary detrusor contraction accompanied by an involuntary contraction of the external 
sphincter, which prevents adequate voiding and which might lead to a low compliant and 
thick-walled bladder, elevated retrograde pressures in the ureter and pelvis, hydronephrosis, 
renal scarring and terminal kidney failure. Without adequate treatment, more than 50% of 
men with DSD will develop severe complications, while these complications are less 
common in women, perhaps due to lower detrusor pressures. (21) DSD is frequently 
encountered in MS and is one of the main urodynamic dysfunction in this disease. (22) The 
rationale for using BTX in the treatment of DSD was extrapolated from studies on patients 
with spinal cord injuries which showed that BTX decreases detrusor and urethral pressures 
and reduces post-voiding residual urine volume. (23) However, the first multicenter 
randomized, double blind, placebo-controlled study with BTX in MS patients who had 
chronic urinary retention and post-voiding residual urine volume between 100 and 500 ml 
showed negative results. (24) Those patients received a single transperineal injection of either 
BTX (100 U Botox®) or placebo in the sphincter: BTX significantly increased voiding 
volume (+54%, p = 0.02) and reduced pre-micturition (229%, p = 0.02) and maximal (221%, 
p = 0.02) detrusor pressures compared to placebo. Those authors concluded that a single 
injection of BTX (100 U Botox®) does not decrease post-voiding residual urine volume in 
MS patients with DSD. 
 On the other hand, given that partial spinal cord lesions are a hallmark of MS, the 
clinical picture is usually dominated by symptoms caused by detrusor overactivity (DO), 
namely, urinary urgency and urgency incontinence. In a one-center prospective study on 16 
patients with 300 U of BTX (Botox®) into the bladder and into the external sphincter muscle 
authors have showed that BTX detrusor injections are very effective in the treatment of drug-
resistant DO symptoms. (25) However build up of residual urine remains a problem of which 
patients must be informed. Another single-center, prospective, open-label study using 
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detrusor injections of 300 U of Botox® in patients with MS showed highly significant 
improvements in incontinence episodes and urinary urgency, daytime frequency and nocturia, 
and significant improvements in urodynamically demonstrated bladder function, as well as 
sustained improvements in all quality of life scores. The mean duration of effect was 9.7 
months and similar results were seen with repeat treatments. (26) Ehren and coworkers 
performed a randomized, double blind, placebo-controlled study in patients with incontinence 
due to neurogenic DO (including MS patients) in order to evaluate the effect of a single 
injection of 500 U of BTX (Dysport®) on the use of oral rescue medication, bladder 
compliance, continence and quality of life. (27) The results of that study showed that it 
reduced the use of oral medication, high detrusor pressure and frequency of urinary leakage. 
 Other possible indication for BTX in managing urinary symptoms in MS is 
intradetrusor BTX injections for intractable catheter bypassing in patients with neurogenic 
DO. One small study showed that this is a very effective and safe treatment for this 
indication. (28) 
 In conclusion, there is still no evidence that BTX injections are effective in DSD in 
patients with MS. In MS patients with DO, however, BTX injections are effective in reducing 
incontinence episodes and urinary urgency, daytime frequency and nocturia, as well as in 
providing sustained improvements in quality of life parameters. The usual recommended 
Botox® doses are 200-300 U. Several questions still remain unanswered: what is the optimum 
dose? how many injection sites are required? what is the optimum frequency of treatment? It 
should be noted that all the trials that had been conducted thus far have been small in size and 
had a relatively short duration. Therefore, further studies are needed to determine the efficacy 
and tolerability of long-term application. 
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Pain 
 
Pain is a common problem for patients with MS. Observational studies of patients 
attending neurology clinics have reported a prevalence of pain between 28.8-86% (29). 
Paroxysmal pain symptoms in MS patients are usually treated with antiepileptics, chronic 
neuropathic pain is treated with tricyclic antidepressants or antiepileptics, and 
musculoskeletal pain is treated with non-steroidal anti-inflammatory drugs and 
physiotherapy. There are several randomized controlled studies on the role of BTX in 
managing pain (30), but no studies have investigated the role of BTX in the management of 
pain specifically in patients with MS. Trigeminal neuralgia occurs in approximately 2% of 
patients with MS, either as a presenting symptom or during an MS relapse. (31)  
The positive role of BTX in managing pain associated with spasticity is discussed in other 
sections. 
 
 
 
Other indications 
 
Tremor is the most frequent movement disorder in MS and is often very difficult to treat. 
Intention tremor is most frequently observed, but postural tremor also occurs. Very few 
studies have evaluated the effect of BTX on essential tremor. Rest, postural, and kinetic 
tremor were evaluated over a 16-week period in a placebo-controlled study using BTX 50 or 
100 U (Botox®). There was significant improvement on the tremor severity rating scale at 
four weeks after injection, with 75% of the BTX-treated patients versus 27% of the placebo-
treated patients (p < 0.05) having reported mild to moderate improvement. (32) There were 
similar results in another multicenter, double blind, controlled trial on 133 patients with 
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essential tremor. (33) Those patients were randomized to receive 50 or 100 U of BTX 
(Botox®) into wrist flexors and extensors, and they were followed for 4 months. The results 
of the study showed significant improvement in postural tremor, but only minimal 
improvement in kinetic tremor and functional assessments.  
 The effectiveness of BTX in head tremor was evaluated in only one study on 10 
patients. In spite of the very small number of patients, the findings indicated that BTX may 
be useful for patients with essential head tremor who have failed to benefit from oral 
medications. (34)  
 Continuous facial myokymia is an infrequent clinical sign that almost always occurs 
in intrinsic brainstem lesions, particularly in MS. Treatment with BTX (Botox®) 2.5 U in the 
upper and lower eyelids, cheek and perioral muscles was shown to be an effective and safe 
approach for the treatment of this disorder in patients with MS, especially when the condition 
is uncomfortable and persistent. (35) 
 Internuclear ophthalmoplegia is another symptom very frequently seen in MS patients 
and one that is very difficult to manage if there is no recovery after corticosteroid treatment. 
In such instances, application of BTX can result in reduction of diplopia and occasional 
improvement of binocular function. These benefits are, however, limited by the need for 
repeated injections and they must be given by a very experienced physician. (36) Severe 
nystagmus is another MS symptom very difficult to manage. Three series reported somewhat 
beneficial results associated with BTX in patients with acquired nystagmus with oscillopsia, 
but with complications such as ptosis and diplopia being limiting factors. (37,38,39). 
 Tinnitus is another symptom in MS and it is potentially treatable with BTX. (40) One small, 
placebo-controlled study showed improvement in tinnitus handicap inventory scores and 
patient subjective results after a 50 U BTX (Botox®) injection equally divided and injected 
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subcutaneously into 3 sites around the ear, compared with placebo, suggesting a possible 
benefit of BTX in tinnitus management. (41) 
Trigeminal neuralgia  appears in  1% of patients with MS in whom it's progression is 
usually faster than in idiopathic trigeminal neuralgia (42).  An open-label study has shown 
that BTX significantly reduces the duration and intensity of pain in cases of intractable 
trigeminal neuralgia, with the peak effect at day 20. BTX was also shown to reduce the use of 
preventive medication: the BTX dose depended on the reported pain surface (6.83 U for the 
ophthalmic branch, 6.45 U for the maxillary branch, and 9.11 for the mandibular branch. (43) 
A randomized controlled trial is needed to validate these results. 
 Gastroparesis is rarely seen in MS and is difficult to treat when it is present. (44) Two 
randomized controlled studies showed that, when compared with placebo, intrapyloric BTX 
injection did not successfully relieve subjective symptoms or improve objective 
measurements in patients with gastroparesis. Thus, at present, there is no evidence to 
recommend BTX injections for alleviation of gastroparesis. (45,46) BTX has already been 
successfully used for the management of chronic, refractory constipation in children and may 
be effective in MS patients as well, but further studies are needed to confirm this. (47) 
 Sialorrhea and hyperhidrosis are other potential indications for the use of BTX 
injections, but there are no studies on its application for MS with those symptoms. (15) As 
well other well known indications for BTX injections like hemifacial spasm or cervical 
dystonia which, although rarely, may be associated with MS, and in such instances should be 
treated with BTX.  
 
Conclusion and discussion 
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Treatment of muscle spasm and DO by means of BTX injections can be recommended based 
on the results of prospective, placebo-controlled studies. It should be borne in mind, however, 
that those studies included small numbers of patients, and were of relatively short duration. 
Although it is potentially useful in the management of other symptoms in MS, BTX should 
be used with caution, and final validation of its effectiveness awaits more prospective, 
placebo-controlled studies. On the other hand, the safety of injected BTX is well established, 
but was not assessed in MS specifically. Fatigue, one of the potential side effects of BTX, 
especially if used in large doses, needed for spasticity treatment (48, 49) MS-related fatigue, 
if aggravated by BTX, can be a severe problem causing interference with home and 
vocational activities. 
Another problem is that BTX is rather expensive treatment and evidence of the cost 
effectiveness of new treatments must be shown for them to be adopted and paid for by 
healthcare services. Similarly MS is very expensive disease. The total mean annual costs per 
patient in Europe is estimated at €18 000 for mild disease (Expanded Disability Status Scale 
(EDSS) <4.0), €36 500 for moderate disease (EDSS 4.0–6.5) and €62 000 for severe disease 
(EDSS >7.0). (50) Cost-effectiveness analysis in multiple sclerosis is, however, not 
straightforward because of the nature of the disease. MS in an advanced stage is associated 
with high costs and low quality of life and clinical benefits of BTX treatment, at least for 
spasticity, (51) outweigh the apparent high costs of this intervention, showing it to be a cost-
effective treatment.  
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